FinHer Breast Cancer Study

Dataset ID Technology Samples
EGAD00001000871 Illumina HiSeq 2000 993

Dataset Description

The purpose of this study is to sequence 500 known cancer genes in 960 newly diagnosed high risk breast cancer patients treated with current standard of care therapies and trastuzumab, for somatic alteration and copy number changes. We will be using next gen sequencing technology to determine the prognostic relevance of these somatic genetic alterations and of teh low frequency events to determine if they are associated with trastuzumab benefit or HER2 positive breast cancer, i.e. treatment interaction. The samples will be analysed adn correlated with clinical variables including outcome.

Data Use Conditions


See further information on Data Use Conditions

Label Code Version Modifier
obsolete general research use and clinical care DUO:0000005 2017-10-16
obsolete research use only DUO:0000014 2017-10-16
publication required DUO:0000019 2017-10-16
user specific restriction DUO:0000026 2017-10-16
institution specific restriction DUO:0000028 2017-10-16